MCID: PPL002
MIFTS: 50

Papillary Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Carcinoma

MalaCards integrated aliases for Papillary Carcinoma:

Name: Papillary Carcinoma 12 15
Carcinoma, Papillary 44 73
Carcinoma Papillary 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3113
MeSH 44 D002291
NCIt 50 C2927
SNOMED-CT 68 189562005 25910003
UMLS 73 C0007133

Summaries for Papillary Carcinoma

Disease Ontology : 12 A carcinoma that is derives from epithelial cells with finger like projections.

MalaCards based summary : Papillary Carcinoma, also known as carcinoma, papillary, is related to primary peritoneal carcinoma and renal cell carcinoma, papillary, 1. An important gene associated with Papillary Carcinoma is TG (Thyroglobulin), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs BCG vaccine and Adjuvants, Immunologic have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Papillary Carcinoma

Diseases related to Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 341)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 33.7 ERBB2 PGR RET
2 renal cell carcinoma, papillary, 1 33.4 BRAF ERBB2 KRT7 MET PAX8
3 breast papillary carcinoma 33.3 ERBB2 NCOA4 PGR RET
4 papillary serous adenocarcinoma 32.2 KRT20 KRT7 NKX2-1 PGR
5 thyroid cancer, nonmedullary, 1 30.8 BRAF LGALS3 NCOA4 NKX2-1 PAX8 RET
6 thyroiditis 30.7 CALCA RET TG TPO TSHR
7 suppurative thyroiditis 30.6 CALCA TG
8 histiocytic sarcoma 30.5 LGALS3 MUC1
9 intracystic papillary adenoma 30.4 ERBB2 PGR
10 thyroid carcinoma, familial medullary 30.2 CALCA NKX2-1 RET TG
11 thymus cancer 30.2 KRT7 MUC1 NKX2-1
12 papillary adenoma 30.1 KRT7 NKX2-1
13 cystic teratoma 30.0 KRT20 KRT7 NKX2-1
14 struma ovarii 29.7 BRAF NKX2-1 RET TG TSHR
15 mucoepidermoid carcinoma 29.7 CALCA ERBB2 KRT7 MUC1 TG
16 subacute thyroiditis 29.7 TG TPO TSHR
17 adenocarcinoma in situ 29.5 KRT20 KRT7 PAX8
18 hyperthyroidism 29.2 TG TPO TSHR
19 ductal carcinoma in situ 29.2 CDH1 ERBB2 MUC1 PGR
20 squamous cell carcinoma 29.1 BRAF CDH1 ERBB2 KRT19 MUC1
21 in situ carcinoma 29.1 CDH1 ERBB2 PGR
22 renal cell carcinoma, nonpapillary 29.1 CDH1 KRT19 KRT20 KRT7 MET MUC1
23 adenocarcinoma 29.0 BRAF CDH1 ERBB2 MUC1 RET
24 malignant struma ovarii 28.9 KRT19 LGALS3 NCOA4 NKX2-1 RET TG
25 lymphoepithelioma-like carcinoma 28.7 CDH1 KRT20 KRT7 MUC1
26 neonatal hypothyroidism 28.6 PAX8 TG TPO TSHR
27 multinodular goiter 28.2 CALCA NKX2-1 PAX8 TG TPO TSHR
28 congenital hypothyroidism 28.2 NKX2-1 PAX8 TG TPO TSHR
29 thyroid cancer, nonmedullary, 2 28.1 BRAF CALCA KRT19 LGALS3 NKX2-1 PAX8
30 hypothyroidism 28.0 CALCA NKX2-1 PAX8 RET TG TPO
31 hashimoto thyroiditis 27.9 CALCA KRT19 LGALS3 RET TG TPO
32 adenoid cystic carcinoma 27.8 CDH1 ERBB2 KRT19 KRT20 KRT7 MUC1
33 goiter 27.7 CALCA LGALS3 NKX2-1 PAX8 TG TPO
34 ovarian cancer 27.3 BRAF CDH1 CLDN3 ERBB2 KRT7 MUC1
35 anaplastic thyroid cancer 27.2 BRAF CDH1 MET NKX2-1 PAX8 TG
36 follicular adenoma 27.2 CALCA KRT19 LGALS3 NKX2-1 PAX8 RET
37 thyroid cancer 23.7 BRAF CALCA CDH1 KRT19 LGALS3 MET
38 tall cell variant papillary carcinoma 12.1
39 gallbladder papillary carcinoma 12.1
40 primary peritoneal serous/papillary carcinoma 12.0
41 ovary papillary carcinoma 12.0
42 thyroid carcinoma, papillary, with papillary renal neoplasia 11.9
43 kidney pelvis papillary carcinoma 11.9
44 familial renal papillary carcinoma 11.9
45 bladder urothelial papillary carcinoma 11.9
46 columnar cell variant papillary carcinoma 11.9
47 papillary carcinoma of the cervix uteri 11.9
48 penis papillary carcinoma 11.8
49 papillary carcinoma of the corpus uteri 11.8
50 papillary thymic adenocarcinoma 11.2

Graphical network of the top 20 diseases related to Papillary Carcinoma:



Diseases related to Papillary Carcinoma

Symptoms & Phenotypes for Papillary Carcinoma

MGI Mouse Phenotypes related to Papillary Carcinoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 LGALS3 ERBB2 BRAF KRT19 CDH1 KRT7
2 homeostasis/metabolism MP:0005376 10.28 KRT7 LGALS3 ERBB2 BRAF CDH1 PAX8
3 endocrine/exocrine gland MP:0005379 10.26 ERBB2 BRAF KRT19 CDH1 RET PAX8
4 cardiovascular system MP:0005385 10.24 ERBB2 BRAF KRT19 CDH1 NKX2-1 LGALS3
5 growth/size/body region MP:0005378 10.2 CDH1 ERBB2 BRAF KRT19 NKX2-1 PAX8
6 mortality/aging MP:0010768 10.15 CDH1 ERBB2 BRAF KRT19 PGR NKX2-1
7 digestive/alimentary MP:0005381 10.11 ERBB2 BRAF KRT19 CDH1 NKX2-1 LGALS3
8 embryo MP:0005380 10.1 ERBB2 BRAF KRT19 CDH1 PGR PAX8
9 neoplasm MP:0002006 10.02 LGALS3 ERBB2 BRAF KRT19 CDH1 RET
10 limbs/digits/tail MP:0005371 9.95 ERBB2 PAX8 MET PGR TSHR RET
11 normal MP:0002873 9.81 ERBB2 BRAF KRT19 CDH1 NKX2-1 PAX8
12 no phenotypic analysis MP:0003012 9.8 KRT19 CDH1 PGR NKX2-1 PAX8 MET
13 reproductive system MP:0005389 9.7 CLDN3 LGALS3 ERBB2 BRAF KRT19 CDH1
14 skeleton MP:0005390 9.28 ERBB2 BRAF KRT19 NKX2-1 LGALS3 PAX8

Drugs & Therapeutics for Papillary Carcinoma

Drugs for Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Investigational Phase 3
2 Adjuvants, Immunologic Phase 3
3 Vaccines Phase 3
4 Alkylating Agents Phase 3,Phase 2
5 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
6 Antibiotics, Antitubercular Phase 3,Phase 2
7 Mitomycins Phase 3
8 Nucleic Acid Synthesis Inhibitors Phase 3
9
Everolimus Approved Phase 2 159351-69-6 6442177
10
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
11
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
12
Iodine Approved, Investigational Phase 2,Phase 1,Not Applicable 7553-56-2 807
13
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
14
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2 33069-62-4 36314
15
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
16
Lenvatinib Approved, Investigational Phase 2 417716-92-8
17
Pembrolizumab Approved Phase 2 1374853-91-4
18
Trametinib Approved Phase 2 871700-17-3 11707110
19
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
20
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
21
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
22
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
23 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
24 Anti-Infective Agents, Local Phase 2,Not Applicable
25 Hormones Phase 2,Not Applicable
26 Antifungal Agents Phase 2
27 Immunosuppressive Agents Phase 2,Phase 1
28 Antineoplastic Agents, Alkylating Phase 2
29 Bendamustine Hydrochloride Phase 2
30 cadexomer iodine Phase 2,Phase 1,Not Applicable
31 Antibodies Phase 2
32 Deoxyglucose Phase 2
33 Endothelial Growth Factors Phase 2
34 Fluorides Phase 2
35 Fluorodeoxyglucose F18 Phase 2,Phase 1
36 Immunoglobulins Phase 2
37 Mitogens Phase 2
38 Radiopharmaceuticals Phase 2,Phase 1
39 Angiogenesis Inhibitors Phase 2,Phase 1
40 Angiogenesis Modulating Agents Phase 2,Phase 1
41
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
42 Protein Kinase Inhibitors Phase 2,Phase 1
43 Albumin-Bound Paclitaxel Phase 1, Phase 2,Phase 2
44 Micronutrients Phase 2,Not Applicable
45 Trace Elements Phase 2,Not Applicable
46 Antimitotic Agents Phase 1, Phase 2,Phase 2
47 Antineoplastic Agents, Phytogenic Phase 1, Phase 2,Phase 2
48 Antibodies, Monoclonal Phase 2
49
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
50
Ethanol Approved Not Applicable 64-17-5 702

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
2 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
3 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
4 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
5 Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumor Not yet recruiting NCT03335059 Phase 3
6 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe Completed NCT00688753 Phase 2 RAD001
7 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe Completed NCT00688623 Phase 2 Everolimus
8 Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer Completed NCT00867503 Phase 2 Bendamustine HCL
9 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed NCT00559949 Phase 2 Selumetinib
10 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
11 pazopanib_NCRCC,Ph2 STUDY Completed NCT01538238 Phase 2 pazopanib
12 Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer Completed NCT00425386 Phase 2 erlotinib hydrochloride;sunitinib malate
13 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
14 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
15 Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
16 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
17 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
18 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
19 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Active, not recruiting NCT01367002 Phase 2 Carboplatin/Paclitaxel;Trastuzumab
20 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2 ferumoxtran-10
21 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
22 Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib Malate
23 Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Not yet recruiting NCT03506048 Phase 2 Lenvatinib
24 Toremifene in Treating Patients With Ovarian Cancer Withdrawn NCT00003865 Phase 2 toremifene
25 Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery Completed NCT00448643 Phase 1 Cisplatin
26 Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors Terminated NCT02313012 Phase 1 CC-90003
27 Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma Unknown status NCT02648399 Not Applicable
28 Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid Unknown status NCT00984191 Not Applicable
29 Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy Unknown status NCT02768753
30 Influence of Thyroid Hormones on the Woundhealing Process Unknown status NCT00929318 Not Applicable
31 Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis Unknown status NCT01384669
32 Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma Unknown status NCT01974284 Not Applicable percutaneous ethanol ablation
33 Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients Completed NCT01150318 Not Applicable Administration of 131 iodine
34 APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. Completed NCT02323724
35 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study Completed NCT01927887 Not Applicable Ferumoxytol
36 Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors Completed NCT00001668
37 Long-term Outcomes of Total Thyroidectomy Versus Less Than Total Thyroidectomy for Papillary Thyroid Microcarcinoma Completed NCT01648569
38 A Gene Hunting Study for Familial Papillary Thyroid Cancer Recruiting NCT02776969
39 Active Surveillance of Papillary Thyroid Microcarcinoma Recruiting NCT02609685 Not Applicable
40 Active Surveillance on Papillary Thyroid Microcarcinoma Recruiting NCT02938702
41 Active Surveillance of Papillary Thyroid Microcarcinoma Recruiting NCT02952612
42 Expression of Protein Convertases in Thyroid Nodules Enrolling by invitation NCT03160482
43 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Not yet recruiting NCT02774395
44 A Trial Comparing USG-HIFU vs AS in Management of Low-risk PTMC Not yet recruiting NCT03327636 Not Applicable
45 Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma Not yet recruiting NCT03432299 Not Applicable

Search NIH Clinical Center for Papillary Carcinoma

Cochrane evidence based reviews: carcinoma, papillary

Genetic Tests for Papillary Carcinoma

Anatomical Context for Papillary Carcinoma

MalaCards organs/tissues related to Papillary Carcinoma:

41
Thyroid, Lymph Node, Breast, Kidney, Ovary, Lung, Endothelial

Publications for Papillary Carcinoma

Articles related to Papillary Carcinoma:

(show top 50) (show all 804)
# Title Authors Year
1
Coexistent cutaneous myeloid sarcoma in a patient with invasive papillary carcinoma of thyroid - A rare presentation. ( 29855456 )
2018
2
Solid Papillary Carcinoma of the Breast: Magnetic Resonance Mammography, Digital Mammography, and Ultrasound Findings. ( 29613993 )
2018
3
Papillary carcinoma in thyroglossal duct cyst: Diagnosis by fine-needle aspiration cytology and immunocytochemistry. ( 29737627 )
2018
4
Papillary Carcinoma of Thyroid with Nasal Cavity Metastases: A Case Report. ( 29398758 )
2018
5
Paratesticular Serous Papillary Carcinoma of High Grade and Malignant Potential: A Rare Case with a Role for Adjuvant Therapy. ( 29662727 )
2018
6
Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases. ( 29785016 )
2018
7
Intracystic papillary carcinoma of the male breast: a case report. ( 29361955 )
2018
8
Mammographic and ultrasound findings in poroid hidradenoma of the breast mimicking intraductal papilloma and papillary carcinoma: A case report. ( 29924021 )
2018
9
Preoperative injection of carbon nanoparticles is beneficial to the patients with thyroid papillary carcinoma: From a prospective study of 102 cases. ( 29979421 )
2018
10
Expression and Distribution of Galectin-3 in Chromophobe and Papillary Carcinomas. ( 29277781 )
2018
11
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease. ( 29887709 )
2018
12
Magnetic Resonance Imaging Features of Breast Encapsulated Papillary Carcinoma. ( 29787497 )
2018
13
Encapsulated papillary carcinoma of the breast: A clinicopathological study of 49 cases. ( 29731165 )
2018
14
Papillary Carcinoma of Stensen's Duct with Intestinal Differentiation. ( 29774486 )
2018
15
Apocrine Encapsulated Papillary Carcinoma of the Breast: The First Reported Case with an Infiltrative Component. ( 29963120 )
2018
16
LncRNA BISPR promotes the progression of thyroid papillary carcinoma by regulating miR-21-5p. ( 29856242 )
2018
17
Early Local Recurrence in a Patient With Encapsulated Papillary Carcinoma of the Breast. ( 29803324 )
2018
18
Acute suppurative thyroiditis caused by thyroid papillary carcinoma in the right thyroid lobe of a healthy woman. ( 29785209 )
2018
19
Papillary Carcinoma Thyroid Presenting as Huge Scalp Metastases. ( 29643664 )
2018
20
Transoral videolaryngoscopic surgery for papillary carcinoma arising in lingual thyroid. ( 29776698 )
2018
21
Invasive Thyroglossal Duct Cyst Papillary Carcinoma: A Case Report and Review of the Literature. ( 29950556 )
2018
22
Encapsulated Papillary Carcinoma in A Man with Gynecomastia: Ultrasonography, Mammography and Magnetic Resonance Imaging Features with Pathologic Correlation. ( 29774323 )
2018
23
Evaluation of the presence of Epstein-Barr virus (EBV) in Iranian patients with thyroid papillary carcinoma. ( 28554750 )
2017
24
Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory BehAset disease uveitis and concomitant bladder papillary carcinoma. ( 28891187 )
2017
25
Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze. ( 29150742 )
2017
26
Anaplastic Spindle Cell Squamous Carcinoma Arising from Tall Cell Variant Papillary Carcinoma of the Thyroid Gland: A Case Report and Review of the Literature. ( 28484653 )
2017
27
Rosettes in papillary carcinoma of thyroid: A rare cytomorphological indicator of aggressive variants. ( 29165889 )
2017
28
Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma. ( 28521457 )
2017
29
Hashimoto's thyroiditis - an independent risk factor for papillary carcinoma. ( 28964693 )
2017
30
Papillary carcinoma in struma ovarii. ( 28251552 )
2017
31
An Indian Tertiary Care Hospital Scenario of Papillary Carcinoma of Thyroid. ( 28764174 )
2017
32
18F-FDG PET/CT of Papillary Carcinoma in a Lateral Thyroglossal Duct Cyst. ( 28525461 )
2017
33
Solid papillary carcinoma of the breast with an associated Cytokeratin 7- negative Paget's disease of the nipple. Report of a first case. ( 29265587 )
2017
34
Infiltrating Ductal Carcinoma Co-Existing with Intraductal Papillary Carcinoma of Male Breast: A Rare Case Report. ( 28764176 )
2017
35
Thyroid cancer: Overdiagnosis of papillary carcinoma - who benefits? ( 28059158 )
2017
36
Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation. ( 28731042 )
2017
37
Warthin-like papillary carcinoma associated with Hashimoto thyroiditis and systemic granulomatosis: a case report. ( 29512805 )
2017
38
Cytodiagnosis of papillary carcinoma of the male breast: Report of a case with histological correlation. ( 28469321 )
2017
39
A confusing lesion of thyroid papillary carcinoma. ( 29446823 )
2017
40
Papillary Carcinoma Arising in a Thyroglossal Duct Cyst. ( 28492409 )
2017
41
A potential role for the Hippo pathway protein, YAP, in controlling proliferation, cell cycle progression, and autophagy in BCPAP and KI thyroid papillary carcinoma cells. ( 28804541 )
2017
42
Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma. ( 28789361 )
2017
43
Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma. ( 28451753 )
2017
44
Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid-papillary carcinoma. ( 28770103 )
2017
45
The relationship between the expressions of tumor associated fibroblasts Cav-1 and MCT4 and the prognosis of papillary carcinoma of breast. ( 28625953 )
2017
46
Papillary carcinoma of the thyroid in patients with primary hyperparathyroidism: Is there a link? ( 28571792 )
2017
47
A Case of Thyroid Papillary Carcinoma: Remarkable Decrease in Multiple Lung Metastases within 40 Years after a Single Administration of Radioiodine without Thyroidectomy and with Later Anaplastic Transformation. ( 29279694 )
2017
48
Long-term outcome of thyroid lobectomy for unilateral multifocal papillary carcinoma. ( 28682915 )
2017
49
Warthin-like variant of thyroid papillary carcinoma. ( 28923670 )
2017
50
Impact of the Reclassification of the Non-Invasive Follicular Variant of Papillary Carcinoma as Benign on the Malignancy Risk of the Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis Study. ( 28445876 )
2017

Variations for Papillary Carcinoma

Expression for Papillary Carcinoma

Search GEO for disease gene expression data for Papillary Carcinoma.

Pathways for Papillary Carcinoma

GO Terms for Papillary Carcinoma

Cellular components related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 CLDN3 ERBB2 MET MUC1 RET TPO
2 receptor complex GO:0043235 8.92 ERBB2 MET RET TSHR

Biological processes related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.73 BRAF ERBB2 MET RET
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.62 BRAF ERBB2 MET RET
3 negative regulation of signal transduction GO:0009968 9.46 BRAF ERBB2 MET RET
4 positive regulation of kinase activity GO:0033674 9.43 ERBB2 MET RET
5 hormone biosynthetic process GO:0042446 9.4 TG TPO
6 entry of bacterium into host cell GO:0035635 9.37 CDH1 MET
7 thyroid-stimulating hormone signaling pathway GO:0038194 8.96 PAX8 TSHR
8 thyroid gland development GO:0030878 8.92 BRAF NKX2-1 PAX8 TG

Molecular functions related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 BRAF CALCA CDH1 CLDN3 ERBB2 MET
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 ERBB2 MET RET
3 MAP kinase kinase kinase activity GO:0004709 9.26 BRAF ERBB2 MET RET
4 thyroid-stimulating hormone receptor activity GO:0004996 9.16 PAX8 TSHR
5 mitogen-activated protein kinase kinase binding GO:0031434 8.92 BRAF ERBB2 MET RET

Sources for Papillary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....